Infuturia Global Ltd. v. Sequus Pharmaceuticals, Inc.

631 F.3d 1133, 2011 U.S. App. LEXIS 2337, 2011 WL 353214
CourtCourt of Appeals for the Ninth Circuit
DecidedFebruary 7, 2011
Docket09-16378
StatusPublished
Cited by35 cases

This text of 631 F.3d 1133 (Infuturia Global Ltd. v. Sequus Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Infuturia Global Ltd. v. Sequus Pharmaceuticals, Inc., 631 F.3d 1133, 2011 U.S. App. LEXIS 2337, 2011 WL 353214 (9th Cir. 2011).

Opinion

OPINION

N.R. SMITH, Circuit Judge:

In this appeal, we primarily address the novel question whether, under 9 U.S.C. § 205, a district court has removal jurisdiction 1 over a case where the defendant raises an affirmative defense related to an arbitral award falling under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards, June 10, 1958, 21 U.S.T. 2517, 330 U.N.T.S. 38 as implemented by 9 U.S.C. § 201 et seq. (“Convention”). 2 Because an arbitration agreement or award falling under the Convention “relates to” the subject matter of an action whenever it could conceivably affect the outcome of the plaintiffs suit, a district court does have removal jurisdiction over such a ease.

I. Factual and Procedural Background

This case arises from a dispute over medical licensing rights between Appellant Infuturia Global Ltd. (“Infuturia”), a citizen of the British Virgin Islands; Yissum Research and Development Co. (“Yissum”), a citizen of Israel; and Appellee Sequus Pharmaceuticals, Inc. (“Sequus”), a citizen of California. In the 1980s, Professor Yechezkel Barenholz (“Barenholz”) of The Hebrew University of Jerusalem (the “University”) and Yissum developed technologies in Israel using liposomes as a vehicle for delivering pharmaceuticals to the human body. In March of 1990, Infuturia entered into a license agreement (“Infuturia License”) with Yissum exchanging royalties for an exclusive worldwide right to develop, market, and use certain Yissum patents. The agreement included an arbitration provision requiring arbitration of any dispute “connected in any way to the implementation of [the] Agreement.” In January of 1995, Sequus entered into a licensing agreement (“Sequus License”) with Yissum for rights to certain liposome technology owned by Yissum. Barenholz and Yissum had previously worked with Sequus on liposome research.

On October 26, 1998, Infuturia sued Sequus, the University, and Barenholz in California state court alleging tortious interference with the Infuturia License. Yissum was not named as a defendant. Infuturia alleged that the defendants had interfered with the Infuturia License by *1136 encouraging Yissum to divulge and license technology that was already licensed to Infuturia. Though not a party to the California proceedings, Yissum petitioned for a stay pending arbitration pursuant to the arbitration provision in the Infuturia License. The California state court granted the stay on July 15, 1999. In an Israeli arbitration, Infuturia alleged claims similar to those asserted in the California state court proceedings, namely that Yissum breached the Infuturia License by developing, patenting, and selling technology related to or based on technology already licensed to Infuturia. 3 After completing the arbitration, the arbitrator determined, among other things, that (1) Infuturia’s license was valid, (2) Yissum had not breached the Infuturia License, and (3) Infuturia did not have rights to any patents and products relating to the Sequus License.

Given the arbitration decision, the state court lifted the stay in the California case. Infuturia then filed a First Amended Complaint in state court which was similar to the original state court complaint, but did not reference certain Sequus products the arbitrator determined were not related to the Infuturia License. The University and Barenholz subsequently filed a Notice of Removal (in which Sequus joined), pursuant to 9 U.S.C. § 205. Infuturia filed a motion to remand, arguing only that removal was improper under 9 U.S.C. § 205, because the defendants were not parties to the foreign arbitration agreement between Infuturia and Yissum. In February 2009, the court denied the motion to remand. The district court found that removal was proper because the litigation “relates to” the arbitration provision and the arbitration provision falls under the Convention. The court also found that Infuturia’s pleadings were vague and ordered Infuturia to file a second amended complaint identifying the particular Sequus products, compounds, or inventions that allegedly infringe upon Infuturia’s license with Yissum.

Infuturia filed its Second Amended Complaint on March 16, 2009. It asserted tortious interference and conversion claims and only named Sequus as a defendant. In its Answer to the Second Amended Complaint, Sequus raised the affirmative defense of collateral estoppel, arguing that these issues had already been resolved against Infuturia in the Israeli arbitration. When it filed its Answer, Sequus also moved to dismiss under Rule 12(b)(6) for failure to state a claim and Rule 12(b)(7) for failure to join a necessary party. The district court granted both motions on June 1, 2009. Infuturia appeals the district court’s grant of both motions, asserts that removal was improper under 9 U.S.C. § 205, and argues that the district court lacked federal subject-matter jurisdiction. 4

II. Subject Matter Jurisdiction

Infuturia first contends the district court lacked subject matter jurisdiction over this case. The district court identified 9 U.S.C. § 203 as the basis for jurisdiction in its order granting Sequus’s motions to dismiss. Sequus agrees with the district court, but argues for jurisdiction under both §§ 203 and 205, as well as diversity jurisdiction under 28 U.S.C. § 1332(a)(2). Because we conclude the *1137 district court had diversity jurisdiction, we do not reach the other contended bases for subject matter jurisdiction under §§ 203 and 205.

Infuturia argues that diversity jurisdiction does not lie under 28 U.S.C. § 1332(a)(2) because (1) jurisdiction is determined at the time of removal, and the parties were not diverse when this case was removed to federal court; and (2) Sequus, as a forum defendant, could not have originally removed the case to federal court even if it had been the only defendant sued. We disagree with Infuturia’s arguments, because they raise statutory rather than jurisdictional objections. Both the forum defendant rule and the requirement for diversity at the time of removal are statutory requirements imposed by the general removal statute, 28 U.S.C. § 1441, not jurisdictional requirements. See Grupo Dataflux v. Atlas Global Group, L.P., 541 U.S.

Related

Cite This Page — Counsel Stack

Bluebook (online)
631 F.3d 1133, 2011 U.S. App. LEXIS 2337, 2011 WL 353214, Counsel Stack Legal Research, https://law.counselstack.com/opinion/infuturia-global-ltd-v-sequus-pharmaceuticals-inc-ca9-2011.